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Abstract
Tetrahydrouridine (THU) is a well characterized and potent inhibitor of cytidine deaminase (CDA). Highly expressed CDA
catalyzes and inactivates cytidine analogues, ultimately contributing to increased gemcitabine resistance. Therefore,
a combination therapy of THU and gemcitabine is considered to be a potential and promising treatment for tumors with
highly expressed CDA. In this study, we found that THU has an alternative mechanism for inhibiting cell growth which is
independent of CDA expression. Three different carcinoma cell lines (MIAPaCa-2, H441, and H1299) exhibited decreased cell
proliferation after sole administration of THU, while being unaffected by knocking down CDA. To investigate the mechanism
of THU-induced cell growth inhibition, cell cycle analysis using flow cytometry was performed. This analysis revealed that
THU caused an increased rate of G1-phase occurrence while S-phase occurrence was diminished. Similarly, Ki-67 staining
further supported that THU reduces cell proliferation. We also found that THU regulates cell cycle progression at the G1/S
checkpoint by suppressing E2F1. As a result, a combination regimen of THU and gemcitabine might be a more effective
therapy than previously believed for pancreatic carcinoma since THU works as a CDA inhibitor, as well as an inhibitor of cell
growth in some types of pancreatic carcinoma cells.
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Introduction
Pancreatic carcinoma is the fourth leading cause of cancer-
related deaths in the United States. In 2010, the number of newly
diagnosed cases of pancreatic carcinoma was estimated to be
43,140 with 36,800 deaths resulting from related complications
[1]. Unfortunately, a dismal 20% of all patients are candidates for
surgical resection [2], while unresectable cases generally receive
chemotherapy comprised of a standard gemcitabine regimen
(29,29-difluorocytidine). Despite gemcitabine’s effectiveness, almost
all patients have an advanced stage disease that is inherently
resistant or acquires resistance to gemcitabine [3–5]. The vexing
aspects of the disease support the urgent need for further
exploration into the mechanisms conferring this resistance. A
better understanding of these mechanisms will play an important
role in overcoming gemcitabine resistance and help combat a bleak
survival rate. Some studies have shown that gemcitabine resistance
is associated with cytidine deaminase (CDA) [6–8]. CDA is the
catabolic enzyme of gemcitabine which eventually transforms it to
an inactive metabolite (29,29-difluorodeoxyuridine). Tetrahydrour-
idine (THU), a well known and potent inhibitor of CDA,
competitively blocks the enzyme’s active site more effectively than
intrinsic cytidine [9,10]. Previous reports suggest that a combina-
tion therapy of gemcitabine and THU is more effective for several
types of cancer [11–13] due to the maintenance of gemcitabine’s
half-life [14–16]. In this study, CDA expression was measured in
three different pancreatic carcinoma cell lines (Panc-1, MIAPaCa-
2, and BxPC-3). CDA was expressed higher in BxPC-3 compared
to both Panc-1 and MIAPaCa-2. THU was used in a cytotoxic
assay to increase gemcitabine sensitivity. Unexpectedly, MIA-
PaCa-2 cells showed increased gemcitabine sensitivity upon THU
exposure despite having a 1,000-fold lower level of CDA mRNA
compared to BxPC-3. Additionally, we found that MIAPaCa-2
cell growth was inhibited by sole administration of THU. To
further demonstrate this relationship, we confirmed THU’s
function as a cell growth inhibitor in lung carcinoma cell lines.
Our results showed that THU suppressed cell growth in H441 and
H1299 cell lines. We then investigated the mechanism of THU-
induced cell growth inhibition in both pancreatic and lung
carcinoma cell lines, and hypothesized that THU could be an
independent inhibitor of tumor cell proliferation in spite of being
known as a harmless drug to humans.
Materials and Methods
Drugs and chemicals
Gemcitabine (difluorodeoxycytidine, dFdC) was kindly gifted by
Eli Lilly (Indianapolis, IN, USA). Tetrahydrouridine was pur-
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powder and stored at 220uC. Both drugs were dissolved in sterile
distilled water and diluted in culture medium before being used.
Cell lines
The following human pancreatic and lung carcinoma cell lines
were used in this study: Panc-1, MIAPaCa-2, BxPC-3, H322,
H441, and H1299. All cell lines were obtained from the American
Type Culture Collection (Rockville, MD). Panc-1 and MIAPaCa-
2 cells were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and
antibiotics (100 mg/ml penicillin and 100 mg/ml streptomycin).
BxPC-3, H322, H441, and H1299 cells were cultured in RPMI
1640 with the same supplements. All cell lines were routinely
passaged as monolayers at 37uC in a humidified atmosphere of
95% air and 5% CO2.
RNA preparation and RT-PCR (Real-Time Quantitative
PCR)
Total RNA was extracted from cultured cells using Trizol
(Invitrogen: Tokyo, Japan) according to the manufacturer’s
recommendations. Cell pellets were suspended in a 1 ml aliquot
of Trizol per one well of a 6-well plate. 6 mg of the isolated RNA
was used for reverse transcription (GE Health Care, Buckingham-
shire, UK) utilizing random primers (6 mer) according to the
manufacturer’s protocol. cDNA samples were diluted and stored
at 220uC until needed. Gene expression levels were measured
with Taqman real-time polymerase-chain reaction (Applied
Biosystems: Foster City, CA) containing custom-designed probes
for 2 genes (CDA, ID: Hs00156401_m1; and E2F1, ID:
Hs00174164_m1) and GAPDH (ID: Hs99999901_s1) as an
internal control. The expression levels of respective cells were
analyzed using the relative quantification (DD Ct) method. Each
sample was assayed in triplicate.
Gemcitabine chemo-sensitivity with tetrahydrouridine
(THU)
A drug sensitivity assay was performed essentially as described
in a previous report [11]. Cells were seeded in 96-well plates at
2,500,5,000 cells/well in triplicate. After incubating for 12 hrs,
cell viability was determined by treating cells with stepwise 4-fold
serial dilutions of gemcitabine (from 100 mM), and incubating at
37uC for 96 hrs with or without THU. To evaluate cell viability,
all cells were fixed with 25% glutaraldehyde for 30 min at room
temperature and then stained with 200 ml of 0.05% methylene
blue for 20 min. The dye was eluted with 0.33 M HCl for 20 min
with agitation. Absorbance was measured in a microplate reader
(model 3550, Bio-Rad, Tokyo, Japan) at 598 nm. The 50%
inhibitory concentration for cell growth (IC50) was calculated.
Figure 1. Inhibition of cytidine deaminase (CDA) contributes to improved gemcitabine sensitivity. A. Levels of CDA mRNA in pancreatic
and lung carcinoma cell lines were evaluated by real-time PCR for Panc-1, MIAPaCa-2, BxPC-3, H322, H1299, and H441. Normalized DCt was calculated
as 35-(CDA Ct-GAPDH Ct). B. Three pancreatic and three lung cancer cell lines were cultured with just gemcitabine (GEM) alone, or with GEM and
100 mM tetrahydrouridine (THU). IC50 was determined using a colorimetric assay as described in the experimental procedures. Values are means 6
SD, and results are representative of 3 independent experiments.
doi:10.1371/journal.pone.0037424.g001
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PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37424Figure 2. Tetrahydrouridine (THU) inhibits cell growth in MIAPaCa-2, H1299, and H441. Tetrahydrouridine (THU) significantly reduced cell
growth by colorimetric assay in MIAPaCa-2, H441, and H1229 cell lines as compared with the respective control. Values are means of three
independent experiments performed in triplicate. An error bar is presented as S.D. Day4 data were used for the statistical analysis.
doi:10.1371/journal.pone.0037424.g002
Figure 3. Metabolic pathway of gemcitabine. Gemcitabine (29,29-difluorodeoxycytidine, dFdC) is taken in DNA through the active diphosphate
(dFdCDP) and triphosphate (dFdCTP) by deoxycytidine kinase (dCK). dFdCTP can inhibit ribonucleotide reductase (RR). On the contrary, Cytidine
deaminase (CDA) inactivates dFdC to 29,29-difluorodeoxyuridine (dFdU) by deamination. Tetrahydrouridine (THU) prevents dFdC from being
inactivated by binding CDA directly. THU also leads to the potential for cell growth inhibition.
doi:10.1371/journal.pone.0037424.g003
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Cell growth for pancreatic and lung carcinoma cell lines was
carried out using the colorimetric methylene blue assay in 96-well
plates at a density of 5,000 cells/well. Cells were either exposed or
not exposed to THU, counting the first 12 hrs as Day 0. Mean
values were calculated from three different wells in triplicates for
four days.
Cell cycle analysis by flow cytometry
For cell cycle analysis by flow cytometry, cells were seeded in
a 10 cm dish at 60% confluency. After 12 hrs, 100 mM THU was
added to each dish for three days. Cells were then dissociated using
trypsin-EDTA (trypsin 0.25%; EDTA 0.02%) for 2 to 5 min at
37uC, transferred to a 15 mL tube, and washed three times with
PBS. Cells were then fixed overnight in 70% ethanol at 4uC before
being washed again with PBS and resuspended in PBS-triton-
X100 (0.1%). The cells were concomitantly treated with RNaseA
(Sigma Aldrich, San Luis, MO) and stained with propidium
iodide. Cell cycle status was determined using a FACS calibur flow
cytometer (Becton Dickinson, Oxford, UK) and analyzed using
FlowJo-887 software.
Ki-67 staining
To perform Immunocytochemistry (ICC), cells were seeded in
chamber slides at 20–30% confluency. After 12 hrs of incubation,
100 mM tetrahydrouridine (THU) was added for four days. The
Figure 4. THU (Tetrahydrouridine) influences the cell cycle in MIAPaCa-2, H441 and H1299. A. After 3 days of THU exposure, the cell
cycle was analyzed using flow cytometry. In accordance with cells whose growth was inhibited by THU, MIAPaCa-2, H441, and H1229 cell lines
exhibited an increased rate of the G1-phase and a decrease in the S-phase. B. Cells were processed for immuno-cytochemistry with an antibody
against Ki-67. Microscopic images of Ki-67-stained cells are shown in THU-treated cells and non-treated cells. Nuclei were stained with DAB. Data
represents the mean 6 S.D. of 3 independent experiments and significance values relate to comparisons between medium and THU treated cells.
doi:10.1371/journal.pone.0037424.g004
Figure 5. Cytidine deaminase (CDA) inhibition does not participate in cell proliferation. A. After transfecting siRNA against CDA, real-time
PCR analysis of CDA expression in MIAPaCa-2, H441, and H1299 exhibited cell growth inhibition by THU. Statistical significance was confirmed using
a t-test at Day4. B. After knocking down CDA, a proliferation assay was performed. Down-regulated CDA did not affect cell growth in MIAPaCa-2,
H441, and H1229 cell lines. C. A combination therapy of CDA knockdown and THU did not show any differences compared to THU alone.
doi:10.1371/journal.pone.0037424.g005
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4% paraformaldehyde in PBS for 15 min. For permeabilization,
samples were incubated for 10 min with PBS containing 0.3%
Triton X-100. Cells were then treated with a blocking solution
containing 1% BSA in PBS for 60 min. Samples were incubated
for 90 min with the Ki-67 antibody (Abcam, Tokyo, Japan) in
blocking buffer before applying the secondary goat anti-rabbit
antibody for 60 min. Slides were treated with the streptavidin–
biotin complex reagent (Dako, Glostrup, Denmark) for 30 min
and developed with 0.4% diaminobenzidine (DAB)/H2O2. All
stages of the staining process were performed at room temperature
and the slides were washed in PBS. The slides were mounted and
analyzed using light microscopy after stopping the DAB reaction.
The evaluation of ICC staining was performed by counting all
positive reactions in 1000 cells at a magnification of 4006in the
whole cell area.
Transient transfections of cytidine deaminase -siRNA
To knockdown CDA expression in MIAPaCa-2, H441, and
H1299 cells, all cells were seeded at 70–80% confluency in 6-well
plates. Two cytidine deaminase and a negative control siRNAs
were purchased from Invitrogen (Tokyo, Japan). All siRNAs were
individually transfected in each cell line at a final concentration of
60 nM per well with Lipofectamine 2000 (Invitrogen, Tokyo,
Japan). To measure mRNA levels, cells were incubated for 48 hrs
and then harvested for real-time PCR analysis. 12 hrs after
transfecting, cell growth was determined following the procedure
outline above. We also tested whether CDA inhibition plus THU
treatment surpasses the efficiency of THU alone using a pro-
liferation assay. Transfected cells were seeded in a 96-well plate
overnight and THU was added at 100 mM. As prescribed above,
the OD was measured at Day0, 2 and 4.
Immunoblotting analysis
In order to evaluate whether tetrahydrouridine (THU) affects
the cell cycle related factor at the protein level, western blotting
was performed. Four days after adding 100 mM THU or PBS as
a control, protein was extracted from the cell pellet using RIPA
buffer with protease inhibitor (Invitrogen: Tokyo, Japan). Protein
concentration was measured using Bio-Rad protein assay solution.
Equal amounts of total protein were separated using SDS-PAGE
gels under reducing conditions. The protein was then transferred
to a polyvinylidene difluoride (PVDF) membrane (Invitrogen,
Tokyo, Japan) before being blocked with 5% non-fat milk in TBS-
Tween. The membrane was then incubated with primary
antibodies against E2F1 (Santa Cruz, Santa Cruz CA) and b-
actin (Cell Signaling Technology, Tokyo, Japan) at a dilution of
1:1,000. The appropriate primary antibodies were followed by
horseradish peroxidase (HRP)-conjugated secondary antibodies
(Amersham Pharmacia Biotech, Piscataway, NJ) at a dilution of
1:5,000. Visualization was achieved using SuperSignal West
chemiluminescent solution (Pierce, Rockford, IL).
Statistical analyses
All results were conducted in triplicate and carried out on at
least two occasions. Graphpad Prism v5.0 (Graphpad Software
Inc, La Jolla, CA) was used for statistical analysis. Levels of
significance for comparison between all cell lines were determined
by the Student’s t-test distribution or ANOVA analysis. A two-
sided value of ,0.05 was considered significant.
Results
Expression of cytidine deaminase (CDA) using real-time
PCR
mRNA expression of CDA was examined by RT-PCR in all cell
lines. The CDA mRNA level in BxPC-3 was higher than in both
Panc-1 and MIAPaCa-2 cells. H441 had a higher expression level
of CDA than H322 and H1299 (Fig. 1A). All samples were
regarded as evaluable on the basis of GAPDH Ct levels.
Combination therapy with gemcitabine and
tetrahydrouridine (THU) improves gemcitabine sensitivity
in MIAPaCa-2 and H1299 in spite of low cytidine
deaminase (CDA) expression
To test how THU affects the gemcitabine-mediated anti-
neoplastic effect on pancreatic and lung carcinoma cells,
a combination therapy was performed. As expected, high CDA
expression in BxPC-3 and H441 resulted in improved gemcitabine
sensitivity after a 100 mM THU treatment. The sensitivity of
BxPC-3 and H441 cell lines increased by as much as approxi-
mately 2.1 and 4.4 fold respectively. On the other hand,
MIAPaCa-2 and H1299 cells unexpectedly became more sensitive
to gemcitabine with low CDA expression. MIAPaCa-2 and H1299
cells showed a change in IC50 of 2.2 and 2.3 fold respectively.
However, Panc-1 and H322 cells did not show significant changes
in drug sensitivity (Fig. 1B). These data suggested that THU could
Figure 6. Tetrahydrouridine (THU) inhibits E2F1 at the protein
level which is associated with the G1/S transition. Panc-1,
MIAPaCa-2, H441, and H1229 cells were treated with THU (100 mM) for
96 hrs as indicated. Subsequently, E2F1 protein levels were analyzed by
western blotting. THU could down-regulate E2F1 expression. However,
THU did not affect E2F1 mRNA expression level.
doi:10.1371/journal.pone.0037424.g006
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induced cell death regardless of CDA expression levels.
Tetrahydrouridine (THU) controls cell growth
independently
To examine how THU increases gemcitabine sensitivity, even
in cells with low levels of CDA expression, a cell proliferation assay
was performed. We found that THU independently suppressed
tumor proliferation in MIAPaCa-2, H441, and H1299 cells
compared to the control (P=0.0069, 0.0161 and 0.0015 re-
spectively). However, in Panc-1, BxPC-3 and H322 cells, growth
inhibition was not indicated (Fig. 2). A t-test was performed using
data collected at Day4.
Tetrahydrouridine (THU) inhibits S-phase without
apoptosis
Proliferation data collected from cells treated with THU
suggested that THU might have the potential to control cell
growth in the absence of CDA inhibition (Fig. 3). To investigate
how THU inhibits cell growth, flow cytometry was used. The cell
lines which reflected a change in cell growth showed a significant
alteration in the rate of S-phase after adding THU. The rate of
change in S-phase was 6.060.5% (P=0.0023), 5.860.8%
(P=0.0063) and 7.561.5% (P=0.0131) in MIAPaCa-2, H441,
and H1299 cells respectively (Fig. 4A). A paired t-test was used for
evaluating the difference in the S-phase. Because a sub-G1 curve
was not present, we concluded that THU did not induce apoptosis.
Tetrahydrouridine (THU) regulates Ki-67 antigen
Ki-67 antigen expression was consistently altered in the
presence of THU compared to the control in MIAPaCa-2,
H441, and H1299 cells. As indicated by positive nuclear staining,
proliferation rates were decreased with mean values of
15.0%61.5%, 8.3%61.2%, and 15.7%61.2% respectively com-
pared to 28.3%62.4%, 16.7%62.0%, and 27.3%63.0% in the
medium control (Fig. 4B).
Knock-down of cytidine deaminase (CDA) has no
influence on cell proliferation
To examine whether THU affects tumor proliferation through
the inhibition of CDA, two different siRNAs against CDA were
used in this study. Knockdown efficiency was evaluated using real-
time PCR (Fig. 5A). After selecting the most effective siRNA, a cell
growth assay was performed as previously described. Cell pro-
liferation was not significantly altered after sufficiently knocking
down CDA expression, proving that THU-induced growth
inhibition was in a CDA-independent manner (Fig. 5B). More-
over, to investigate whether a combination treatment with CDA
inhibition and THU generates a synergistic or additive effect
compared to THU alone, a proliferation assay under these
conditions was performed. Unfortunately, a difference was not
observed in all the cell lines.
Tetrahydrouridine (THU) controls the G1/S check point
through E2F1
On the basis of data compiled by flow cytometry, we examined
the G1/S check-point related factor by blotting analysis. In
MIAPaCa-2, H441, and H1299 cells, E2F1 expression was
decreased after administering THU compared to the control
(Fig. 6). In contrast, Panc-1 cells did not show a significant change
in intensity. However, other factors including Rb, pRb and cyclin-
E/D were at similar levels in both treatment and control cells
(Data not shown).
Discussion
CDA is a prominent enzyme in the catabolism of cytosine
nucleoside analogues, and is often over-expressed in cancer cells
that have acquired resistance to those analogues [17–19]. The
processing of drugs by CDA typically results in either a loss of
pharmacological activity or the acquisition of undesirable side-
effects. Cumulatively, these issues have stimulated researchers’
interest in the development of superior CDA inhibitors as
therapeutic agents [15,16,20,21]. It has been reported that CDA
levels could predict gemcitabine-induced toxicities, as well as
negative efficacy [22,23]. Some evidence suggests that CDA was
associated with poor prognosis in acute myeloid leukemia [24].
Conversely, a recent report suggested that the CDA single-
nucleotide polymorphism (SNPs), CDA*3 (208 G.A), was
significantly associated with a low level of CDA activity, decreased
gemcitabine clearance, and drug associated toxicities in Japanese
patients [25]. Tibaldi et al. also showed that the CDA Lys27Lys
(AA) polymorphism was associated with better clinical outcome
[26]. Similarly, low plasma CDA activity and heterozygous
CDA*3 were also significantly associated with prolonged overall
survival in advanced pancreatic carcinoma [27]. Accordingly,
down-regulation of CDA plays an important role in deoxycytidine
analogues sensitivity and patient prognosis.
Tetrahydrouridine (THU) is a specific inhibitor of cytidine
deaminase (CDA) which can suppress deamination in the
catabolism of cytotoxic deoxycytidine analogues like ara-C and
gemcitabine [28]. During the 1970s, several clinical trials were
performed with the combination of THU and Ara-C in patients
with acute leukemia [29,30]. It was reported that THU increased
serum Ara-C levels and that the response rates achieved with the
combination were comparable to those with Ara-C alone. A phase
I study on 5-fluoro-29-deoxycytidine (FdCyd) and THU was
recently conducted in patients with advanced solid tumors to
determine its maximum tolerated dose [20]. Even now, several
clinical trials exploring the benefits of combining THU and FdCyd
are still ongoing with support from the National Institutes of
Health (Protocol ID: 09-C-0214, 06-C-0221). CDA is considered
not only a predictive marker of chemo-sensitivity to antitumor
deoxycytidine analogs, but also as a useful target for biochemical
modulation of these analogs. As just described, further THU
research is still expected to produce potentially useful results.
Selection criteria of patients and THU bioavailability are cited as
possible solutions to clinically improve its efficacy. Since several
reports showed that a combination therapy including THU is
effective against highly expressed CDA in cells [11,13], patients
may be selected according to CDA expression. Also, to maximize
the expected advantage of THU, dosage adjustments or the
method of administration might be reconsidered. THU stability is
also an important problem in utilizing THU as efficiency as
possible. It has been suggested that THU bioavailability is
approximately no more than 20% [31]. Beumer et al. have
reported that improved bioavailability has been achieved by
delivering THU as a more lipophilic pro-drug with increased
THU stability from 20% to 30% [31].
Gemcitabine is currently the gold standard treatment for
pancreatic carcinoma despite its efficacy being extremely limited.
Hence, a combination regimen including gemcitabine is desirable
to enhance therapeutic efficacy. Recently, considerable efforts
have been put into the development of molecular targeted drugs
based on the inhibition of growth factor receptors and angiogen-
esis [32–34]. A combination therapy using these drugs is more
effective than gemcitabine alone. However, clinical benefit still
remains insufficient [32–34], and high costs along with the risks of
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factors, existing drugs with reliable efficacy and superior cost
performance, such as thalidomide and hydroxyurea, need to be
reconsidered for tailor-maid therapies [35–41].
In the present study, we found that THU could influence
a tumor’s cell cycle (G1/S phase) in particular cell types. Also, Ki-
67 staining supported the possibility that THU inhibits cell
proliferation, but did not induce apoptosis judging from the results
of flow cytometry and an apoptosis assay (data not shown). A CDA
knockdown experiment indicated that CDA inhibition did not
influence cell proliferation. To be similar efficacy in MIAPaCa-2
was then verified by carrying out the same assays in lung
carcinoma cell lines (H441 and H1299). To examine how THU
controls the G1/S transition, we evaluated the G1/S phase related
protein after THU treatment. Our data suggested that THU itself
could suppress cell growth through the inhibition of E2F1 at the
protein level without inducing apoptosis. The E2F1 protein is
a member of the E2F family of transcription factors, and is
involved in the regulation of cell cycle progression at the G1/S
transition. E2F1 activity is tightly controlled in a cell cycle
dependent manner by the binding of dephosphorylated retino-
blastoma (pRb). In response to mitogenic or non-mitogenic stress
signals, after pRb is phosphorylated by cyclin dependent kinase
(CDK), released E2F1 can activate cell growth promoting genes in
the late G1 phase [42]. We found that THU can control the G1/S
transition through the down-regulation of E2F1.
Finally, a second chemotherapy regimen for advanced pancre-
atic carcinoma is a clinically relevant issue to be resolved urgently.
In this study, we demonstrated that THU acts on some tumor cell
lines to be both A) independently cytotoxic and B) to sensitize
gemcitabine cytotoxicity through E2F1 in both CDA-high and
CDA-low expressing cells. Consequently, THU could improve
gemcitabine sensitivity for at least some gemcitabine resistant cells
regardless of CDA expression. Importantly, THU has been
clinically available, has been established as safe, and is more
reasonably priced than newly developed molecular targeted drugs.
Further research is necessary to discover which cell types are
appropriate for THU treatment to control proliferation. With
improved THU stability in vivo, a combination treatment could be
considered a more feasible and effective therapeutic approach
than existing ones for advanced pancreatic carcinoma.
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